JP2017509323A5 - - Google Patents

Download PDF

Info

Publication number
JP2017509323A5
JP2017509323A5 JP2016549449A JP2016549449A JP2017509323A5 JP 2017509323 A5 JP2017509323 A5 JP 2017509323A5 JP 2016549449 A JP2016549449 A JP 2016549449A JP 2016549449 A JP2016549449 A JP 2016549449A JP 2017509323 A5 JP2017509323 A5 JP 2017509323A5
Authority
JP
Japan
Prior art keywords
amino acid
seq
acid sequence
binding molecule
molecule according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016549449A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017509323A (ja
JP6687526B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2015/052098 external-priority patent/WO2015114150A1/en
Publication of JP2017509323A publication Critical patent/JP2017509323A/ja
Publication of JP2017509323A5 publication Critical patent/JP2017509323A5/ja
Application granted granted Critical
Publication of JP6687526B2 publication Critical patent/JP6687526B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016549449A 2014-02-02 2015-02-02 NGFアンタゴニストドメインおよびTNFαアンタゴニストドメインから構成されるキメラタンパク質 Active JP6687526B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461934828P 2014-02-02 2014-02-02
US61/934,828 2014-02-02
PCT/EP2015/052098 WO2015114150A1 (en) 2014-02-02 2015-02-02 Chimeric protein composed of ngf antagonist domain and a tnfa antagonist domain

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020065513A Division JP7074792B2 (ja) 2014-02-02 2020-04-01 NGFアンタゴニストドメインおよびTNFαアンタゴニストドメインから構成されるキメラタンパク質

Publications (3)

Publication Number Publication Date
JP2017509323A JP2017509323A (ja) 2017-04-06
JP2017509323A5 true JP2017509323A5 (enExample) 2018-03-08
JP6687526B2 JP6687526B2 (ja) 2020-04-22

Family

ID=52440681

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2016549449A Active JP6687526B2 (ja) 2014-02-02 2015-02-02 NGFアンタゴニストドメインおよびTNFαアンタゴニストドメインから構成されるキメラタンパク質
JP2020065513A Active JP7074792B2 (ja) 2014-02-02 2020-04-01 NGFアンタゴニストドメインおよびTNFαアンタゴニストドメインから構成されるキメラタンパク質
JP2022077858A Active JP7520070B2 (ja) 2014-02-02 2022-05-11 NGFアンタゴニストドメインおよびTNFαアンタゴニストドメインから構成されるキメラタンパク質
JP2024109298A Pending JP2024133644A (ja) 2014-02-02 2024-07-08 NGFアンタゴニストドメインおよびTNFαアンタゴニストドメインから構成されるキメラタンパク質

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2020065513A Active JP7074792B2 (ja) 2014-02-02 2020-04-01 NGFアンタゴニストドメインおよびTNFαアンタゴニストドメインから構成されるキメラタンパク質
JP2022077858A Active JP7520070B2 (ja) 2014-02-02 2022-05-11 NGFアンタゴニストドメインおよびTNFαアンタゴニストドメインから構成されるキメラタンパク質
JP2024109298A Pending JP2024133644A (ja) 2014-02-02 2024-07-08 NGFアンタゴニストドメインおよびTNFαアンタゴニストドメインから構成されるキメラタンパク質

Country Status (21)

Country Link
US (5) US9884911B2 (enExample)
EP (2) EP3099713B1 (enExample)
JP (4) JP6687526B2 (enExample)
KR (1) KR102489452B1 (enExample)
CN (2) CN106459190A (enExample)
AU (3) AU2015212787B2 (enExample)
CA (1) CA2938066C (enExample)
CY (1) CY1123248T1 (enExample)
DK (1) DK3099713T3 (enExample)
ES (1) ES2784238T3 (enExample)
HR (1) HRP20200477T1 (enExample)
HU (1) HUE048478T2 (enExample)
LT (1) LT3099713T (enExample)
MX (1) MX382763B (enExample)
PL (1) PL3099713T3 (enExample)
PT (1) PT3099713T (enExample)
RS (1) RS60156B1 (enExample)
RU (1) RU2678810C2 (enExample)
SI (1) SI3099713T1 (enExample)
SM (1) SMT202000182T1 (enExample)
WO (1) WO2015114150A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS60156B1 (sr) 2014-02-02 2020-05-29 Medimmune Ltd Himerni protein sačinjen od ngf antagonist domena i tnfa antagonist domena
US9862760B2 (en) * 2015-09-16 2018-01-09 Novartis Ag Polyomavirus neutralizing antibodies
JP7237945B2 (ja) 2017-09-21 2023-03-13 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Fgf-18部分を含む融合タンパク質
WO2021142573A1 (zh) * 2020-01-13 2021-07-22 丁邦 一种融合蛋白及其制法和用途
KR20230084199A (ko) 2020-09-28 2023-06-12 메디뮨 리미티드 통증 치료를 위한 화합물 및 방법
CN114574444B (zh) * 2020-12-01 2024-05-03 达达生物技术(北京)有限公司 自体纤维母细胞在制备抗类风湿关节炎药物中的应用
TWI821881B (zh) * 2021-01-29 2023-11-11 醫研生物科技有限公司 腫瘤壞死因子α重組抗體及其用途
CN116179667A (zh) * 2022-09-21 2023-05-30 福建中妆技术研究有限公司 基于斑马鱼模型中trpv1信号通路筛选皮肤疼痛舒缓原料的试剂盒及应用

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5681718A (en) 1986-03-14 1997-10-28 Celltech Limited Methods for enhanced production of tissue plasminogen activator in cell culture using alkanoic acids or salts thereof
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
ATE236249T1 (de) 1989-09-12 2003-04-15 Hoffmann La Roche Tfn-bindende proteine
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US7026446B1 (en) * 1997-12-24 2006-04-11 Diatech Pty Ltd. Bifunctional molecules
US20040220103A1 (en) 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
DE19926068C1 (de) * 1999-06-08 2001-01-11 Arne Skerra Muteine des Bilin-Bindungsproteins
KR20040049829A (ko) 2001-05-30 2004-06-12 제넨테크, 인크. 다양한 질환의 치료에 유용한 항-엔지에프 항체
GB0216648D0 (en) 2002-07-18 2002-08-28 Lonza Biologics Plc Method of expressing recombinant protein in CHO cells
ATE497391T1 (de) 2002-10-08 2011-02-15 Rinat Neuroscience Corp Verfahren zur behandlung von postoperativen schmerzen durch verabreichung eines antikörpers gegen nervenwachstumsfaktor und diesen enthaltende zusammensetzungen
US7569364B2 (en) * 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
WO2005075514A2 (en) 2004-03-10 2005-08-18 Lonza Ltd. Method for producing antibodies
CA2581208A1 (en) 2004-08-30 2006-03-09 Lonza Biologics Plc. Affinity- plus ion exchange- chromatography for purifying antibodies
BRPI0606933B8 (pt) 2005-01-24 2021-05-25 Cambridge Antibody Tech Limited membro de ligação específico isolado para fator de crescimento de nervos, molécula de anticorpo isolado, composição e uso de um membro de ligação específico
EP3805269A1 (en) 2006-06-12 2021-04-14 Aptevo Research and Development LLC Single-chain multivalent binding proteins with effector function
GB0624500D0 (en) * 2006-12-07 2007-01-17 Istituto Superiore Di Sanito A novel passive vaccine for candida infections
US7691980B2 (en) 2007-01-09 2010-04-06 Bio-Rad Laboratories, Inc. Enhanced capacity and purification of antibodies by mixed mode chromatography in the presence of aqueous-soluble nonionic organic polymers
EP2158318A2 (en) * 2007-05-14 2010-03-03 Biogen Idec MA, Inc. Single-chain fc (scfc) regions, binding polypeptides comprising same, and methods related thereto
EP2275431A3 (en) 2008-01-18 2011-05-25 Bio-Rad Laboratories, Inc. Enhanced fractionation of phosphorylated and nonphosphorylated biomolecules by apatite chromotography
NZ589434A (en) 2008-06-03 2012-11-30 Abbott Lab Dual variable domain immunoglobulins and uses thereof
CN102149825B (zh) * 2008-07-08 2015-07-22 Abbvie公司 前列腺素e2双重可变结构域免疫球蛋白及其用途
JP2011016676A (ja) * 2009-07-07 2011-01-27 Sumitomo Electric Ind Ltd 窒化物半導体基板の製造方法
MX2012004415A (es) * 2009-10-15 2012-05-08 Abbott Lab Inmunoglobulinas de dominio variable doble y usos de las mismas.
WO2011068993A1 (en) 2009-12-02 2011-06-09 Acceleron Pharma Inc. Compositions and methods for increasing serum half-life of fc fusion proteins.
MX2012011629A (es) * 2010-04-07 2013-03-05 Abbvie Inc Proteinas de union a tnf-alfa.
DK2714738T3 (en) * 2011-05-24 2019-01-28 Zyngenia Inc MULTIVALENT AND MONOVALENT MULTISPECIFIC COMPLEXES AND THEIR APPLICATIONS
JP2014533249A (ja) 2011-11-07 2014-12-11 メディミューン,エルエルシー 多重特異性を持つ多価結合タンパク質およびその使用
EP2797954A2 (en) 2011-12-30 2014-11-05 AbbVie Inc. Dual variable domain immunoglobulins and uses thereof
WO2014106001A2 (en) * 2012-12-28 2014-07-03 Abbvie, Inc. Dual specific binding proteins having a receptor sequence
AU2014227664A1 (en) 2013-03-15 2015-09-24 Abbvie Inc. Dual specific binding proteins directed against TNFalpha
RS60156B1 (sr) 2014-02-02 2020-05-29 Medimmune Ltd Himerni protein sačinjen od ngf antagonist domena i tnfa antagonist domena
CA2874083C (en) * 2014-12-05 2024-01-02 Universite Laval Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases
US20210009671A1 (en) 2019-05-10 2021-01-14 Medimmune Limited Compounds and methods for treating pain

Similar Documents

Publication Publication Date Title
JP2017509323A5 (enExample)
CN111518214B (zh) 靶向cldn18.2的双特异性抗体及其制备方法和应用
CA2903595C (en) Bispecific antibodies specific for fap and dr5, antibodies specific for dr5 and methods of use
CN110305210B (zh) 新型抗体分子、其制备方法及其用途
CN107922486B (zh) 异源二聚体多特异性抗体形式
JP2013515508A5 (enExample)
US12258371B2 (en) Stabilized immunoglobulin domains
HRP20241775T1 (hr) Bispecifična protutijela koja se specifično vežu na pd1 i lag3
RU2018142544A (ru) Биспецифические связывающие белки и пути их применения
JP2017504578A5 (enExample)
JP2010502183A5 (enExample)
JP2014158485A5 (enExample)
IL295295A (en) Antibodies targeting fc receptor-like 5 and methods of use
JP2005518789A5 (enExample)
JP2017520575A5 (enExample)
JP2020515277A5 (enExample)
JP2019502694A5 (enExample)
JP2020524661A5 (enExample)
JP2020524510A5 (enExample)
JP2019535315A5 (enExample)
JP2020502233A5 (enExample)
JP2021512159A5 (enExample)
JP2017534296A5 (enExample)
RU2016132370A (ru) ХИМЕРНЫЙ БЕЛОК, СОСТАВЛЕННЫЙ ИЗ ДОМЕНА АНТАГОНИСТА NGF И ДОМЕНА АНТАГОНИСТА TNFα
CN116940598A (zh) 用于治疗表达cldn18.2的实体瘤的cldn18.2/cd3双特异性抗体